Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sinopharm Group Co., Ltd.
  6. News
  7. Summary
    1099   CNE100000FN7

SINOPHARM GROUP CO., LTD.

(1099)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Boyu, Sinopharm among bidders shortlisted for Mundipharma China - sources

06/08/2021 | 03:54am EDT
FILE PHOTO: The 2020 China International Fair for Trade in Services (CIFTIS) in Beijing

HONG KONG (Reuters) - Drugmaker Mundipharma has included Boyu Capital and state-owned Sinopharm on a shortlist of bidders for its Chinese business, two people familiar with the situation said.

Chinese buyout firms CITIC Capital and CPE are also on the shortlist for Mundipharma's China unit, which sources have said could fetch more than $1 billion.

Mundipharma, which is owned by the billionaire American Sackler family, has chosen about half of around 20 initial possible buyers, including private equity firms and strategic players, to proceed to the next round, one of the people said.

Bids for the second round are non-binding and are due in July, the sources, who declined to be identified as the information is confidential, told Reuters.

A third person close to the situation said remaining bidders also included global and regional private equity firms.

Mundipharma and CPE declined to comment.

A spokesperson for Sinopharm said it could not comment as it did not have any relevant information on the transaction.

Boyu and CITIC Capital did not respond to Reuters queries.

Mundipharma, which is based in Cambridge, Britain, says it has a presence in 120 countries and $2 billion in global sales from drugs for pain management and supportive care, diabetes, oncology and respiratory diseases, among others.

Mundipharma launched in China, where its business now has more than 1,500 employees, in 1993 with a high-profile ceremony at the Great Hall of the People on Tiananmen Square.

Its Beijing factory is the biggest maker of narcotic and psychoactive drugs in the country, its website says, with the painkiller OxyContin one of the Chinese unit's core products.

Deutsche Bank is advising Mundipharma on the sale, Reuters has previously reported. The German bank declined to comment.

(Reporting by Kane Wu; Editing by Anshuman Daga and Alexander Smith)

By Kane Wu


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CITIC LIMITED 1.83% 8.35 End-of-day quote.52.09%
CITIC SECURITIES COMPANY LIMITED 0.41% 24.76 End-of-day quote.-15.78%
DEUTSCHE BANK AG -0.70% 10.84 Delayed Quote.21.13%
ROUND ONE CORPORATION -1.38% 1434 End-of-day quote.54.69%
SINOPHARM GROUP CO., LTD. 3.08% 23.45 End-of-day quote.24.34%
All news about SINOPHARM GROUP CO., LTD.
06/18ASTRAZENECAá : Argentine lab makes first half million doses of Russian COVID-19 ..
RE
06/15SINOPHARM GROUP CO., LTD. : Ex-dividend day for final dividend
FA
06/09China to study using CanSinoBIO COVID shots as a booster
RE
06/08Boyu, Sinopharm among bidders shortlisted for Mundipharma China - sources
RE
06/04Who senior adviser says having "very positive" conversations with sinovac an..
RE
06/02MARKET CHATTER : Sinopharm Can Supply Over 1 Billion COVID-19 Vaccines in H2, Ch..
MT
06/02Bahrain, Facing a Covid Surge, Starts Giving Pfizer Boosters to Recipients of..
DJ
06/02Bahrain Residents Who Are Over 50, Obese, Have Chronic Illnesses Urged To Get..
RE
06/02Bahrain residents who are over 50, obese, have chronic illnesses urged to get..
RE
06/01SINOPHARMá : WHO Grants Emergency-Use Approval to Sinovac's COVID-19 Vaccine
MT
More news
Financials
Sales 2021 527 B 81 434 M 81 434 M
Net income 2021 8 067 M 1 246 M 1 246 M
Net Debt 2021 16 870 M 2 606 M 2 606 M
P/E ratio 2021 9,06x
Yield 2021 3,22%
Capitalization 73 179 M 9 424 M 11 306 M
EV / Sales 2021 0,17x
EV / Sales 2022 0,15x
Nbr of Employees 108 316
Free-Float 43,0%
Chart SINOPHARM GROUP CO., LTD.
Duration : Period :
Sinopharm Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOPHARM GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 23,45 CNY
Average target price 23,87 CNY
Spread / Average Target 1,80%
EPS Revisions
Managers and Directors
NameTitle
Yong Liu President & Executive Director
Xiao Juan Li Chief Financial Officer
Fang Yao Chairman-Supervisory Board
Qing Ming Yu Chairman
Wu Ping Tao Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
SINOPHARM GROUP CO., LTD.24.34%9 141
WALGREENS BOOTS ALLIANCE, INC.29.81%44 750
JD HEALTH INTERNATIONAL INC.-29.60%42 068
MCKESSON CORPORATION9.30%29 402
CARDINAL HEALTH, INC.5.83%16 448
HUADONG MEDICINE CO., LTD72.63%12 452